Duality Biotherapeutics, Inc. (9606) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

9606 Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Duality

Biotherapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

9606 Stock 12 Month Forecast

Average Price Target

HK$346.21

▼(-5.66% Downside)

Based on 3 Wall Street analysts offering 12 month price targets for Duality Biotherapeutics, Inc. in the last 3 months. The average price target is HK$346.21 with a high forecast of HK$500.00 and a low forecast of HK$268.30. The average price target represents a -5.66% change from the last price of HK$367.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"186":"HK$186","501":"HK$501","264.75":"HK$264.8","343.5":"HK$343.5","422.25":"HK$422.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$500.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":346.21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$346.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":268.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$268.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[186,264.75,343.5,422.25,501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,195,218.46153846153845,241.9230769230769,265.38461538461536,288.8461538461538,312.30769230769226,335.7692307692308,359.2307692307692,382.6923076923077,406.15384615384613,429.6153846153846,453.07692307692304,476.53846153846155,{"y":500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,195,206.63153846153847,218.2630769230769,229.89461538461538,241.52615384615385,253.1576923076923,264.78923076923076,276.4207692307692,288.0523076923077,299.68384615384616,311.3153846153846,322.94692307692304,334.5784615384615,{"y":346.21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,195,200.63846153846154,206.27692307692308,211.91538461538462,217.55384615384617,223.1923076923077,228.83076923076925,234.46923076923076,240.10769230769233,245.74615384615385,251.38461538461542,257.0230769230769,262.6615384615385,{"y":268.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":187.2,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":207.4,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":207.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$500.00

Average Price TargetHK$346.21

Lowest Price TargetHK$268.30

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jill WuCMB International Securities

CMB International Securities

HK$270.34

Buy

-26.34%

Downside

Initiated

06/06/25

Promising Investment Opportunity in Duality Biotherapeutics: Strong ADC Pipeline and Strategic Partnerships Justify Buy Rating

Matthew YanCLSA

CLSA

HK$268.3

Buy

-26.89%

Downside

Initiated

05/22/25

CLSA Starts Duality Biotherapeutics (9606:HK) at Outperform (2)CLSA analyst Matthew Yan initiates coverage on Duality Biotherapeutics (9606:HK) with a Outperform (2) rating and a price target of HK$268.30.

Cui CuiJefferies

Jefferies

HK$500

Buy

36.24%

Upside

Initiated

05/21/25

Jefferies Starts Duality Biotherapeutics (9606:HK) at BuyJefferies analyst Cui Cui initiates coverage on Duality Biotherapeutics (9606:HK) with a Buy rating and a price target of HK$500.00.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jill WuCMB International Securities

CMB International Securities

HK$270.34

Buy

-26.34%

Downside

Initiated

06/06/25

Promising Investment Opportunity in Duality Biotherapeutics: Strong ADC Pipeline and Strategic Partnerships Justify Buy Rating

Matthew YanCLSA

CLSA

HK$268.3

Buy

-26.89%

Downside

Initiated

05/22/25

Cui CuiJefferies

Jefferies

HK$500

Buy

36.24%

Upside

Initiated

05/21/25

Jefferies Starts Duality Biotherapeutics (9606:HK) at BuyJefferies analyst Cui Cui initiates coverage on Duality Biotherapeutics (9606:HK) with a Buy rating and a price target of HK$500.00.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Duality Biotherapeutics, Inc.

1 Month

xxx

Success Rate

1/1 ratings generated profit

Average Return

+29.30%

initiated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +29.30% per trade.

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+87.20%

initiated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +87.20% per trade.

1 Year

Cui CuiJefferies

Success Rate

1/1 ratings generated profit

Average Return

+87.20%

initiated a buy rating 3 months ago

Copying Cui Cui's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +87.20% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+87.20%

initiated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +87.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9606 Analyst Recommendation Trends

Rating

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 9606 has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 9606 average Analyst price target in the past 3 months is 346.21.

Each month's total comprises the sum of three months' worth of ratings.

9606 Financial Forecast

No data currently available

9606 Earnings Forecast

Currently, no earnings data available.

No data currently available

9606 Sales Forecast

Currently, no sales data available.

9606 Stock Forecast FAQ

What is HK:9606’s average 12-month price target, according to analysts?

Based on analyst ratings, Duality Biotherapeutics, Inc.’s 12-month average price target is 346.21.

What is HK:9606’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for HK:9606, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Duality Biotherapeutics, Inc. a Buy, Sell or Hold?

Duality Biotherapeutics, Inc. has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Duality Biotherapeutics, Inc.’s share price target?

The average share price target for Duality Biotherapeutics, Inc. is 346.21. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$500.00 ,and the lowest forecast is HK$268.30. The average share price target represents -5.66% Decrease from the current price of HK$367.

What do analysts say about Duality Biotherapeutics, Inc.?

Duality Biotherapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Duality Biotherapeutics, Inc.?

To buy shares of HK:9606, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Duality Biotherapeutics, Inc. (9606) Stock Forecast & Price Target

9606 Analyst Ratings

9606 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Duality Biotherapeutics, Inc.

9606 Analyst Recommendation Trends

9606 Financial Forecast

9606 Earnings Forecast

9606 Sales Forecast

9606 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts